Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of liver transplantations in western countries, with metabolic dysfunction-associated steatohepatitis (MASH) progressing to fibrosis, cirrhosis, and liver failure. Researchers anticipate the approval of the first drug for MASH by 2024, exploring pathways like thyroid hormone receptors and peroxisome proliferator-activated receptors. Phase 3 trials focus on resolving steatohepatitis or improving fibrosis, paving the way for combination therapies and alternative endpoints in clinical trials.
Journal Article by Noureddin M in Hepatology
Copyright © 2024 American Association for the Study of Liver Diseases.